Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11706056 | 0.89 | CYP19A1 (0.46) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL2775692 | 0.85 | CYP19A1 (0.43) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL11707276 | 0.84 | CYP19A1 (0.45) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL11706087 | 0.84 | CYP19A1 (0.45) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL2354714 | 0.82 | CYP19A1 (0.41) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL2352623 | 0.81 | CYP3A4 (0.40) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL11704755 | 0.80 | CYP19A1 (0.44) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL2777367 | 0.78 | NR4A2 (0.45) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL2356494 | 0.77 | CYP19A1 (0.42) | CYP3A4LMNAMAPTKMT2AUSP2 | |
| SCHEMBL2353051 | 0.77 | HDAC8 (0.44) | CYP3A4LMNAMAPTKMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0337929-A1 | N-substituted imidazoles, process for their preparation and their pharmaceutical application | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-10-18 | — | — | EP | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | MOUNT SINAI HOSPITAL (CA) | 2008-02-21 | — | — | US | disclosed |
| US-20080025991-A1 | Use of Aromatase Inhibitors for Treatment of Ectopic Pregnancy | MOUNT SINAI HOSPITAL (CA) | 2008-01-31 | — | — | US | disclosed |
| US-20060069067-A1 | Combination of an aromatase inhibitor with a bisphosphonate | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-20040235812-A1 | Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male | CASPERS ROBERT F (CA) | 2004-11-25 | — | — | US | disclosed |
| US-20040204393-A1 | use of aromatase inhibitor in production of medicament for improving implantation and pregnancy rates for female undergoing assisted reproduction treatment comprising daily doses of aromatase inhibitor for administration during assisted reproduction or ovarian stimulation cycles to reduce serum estradiol | ARES TRADING S.A. (CH) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235812-A1 | Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male | CYP19A1, SHBG, CYP17A1 | CYP3A4 61/4885LMNA 924/4885MAPT 1752/4885 |
| US-20080045484-A1 | Use of Aromatase Inhibitors for Endometrial Thinning in Preparation for Surgical Procedures on the Endometrial Cavity and Uterus | CYP19A1, SHBG, HSD17B11 | CYP3A4 80/4885LMNA 759/4885MAPT 4381/4885 |
| US-20080025991-A1 | Use of Aromatase Inhibitors for Treatment of Ectopic Pregnancy | CYP19A1, HSD17B11, CYP17A1 | CYP3A4 106/4885LMNA 2790/4885MAPT 3791/4885 |
| US-20060069067-A1 | Combination of an aromatase inhibitor with a bisphosphonate | CYP19A1, BRCA1, SHBG | CYP3A4 909/4885LMNA 3219/4885MAPT 4676/4885 |
| US-20040204393-A1 | use of aromatase inhibitor in production of medicament for improving implantation and pregnancy rates for female undergoing assisted reproduction treatment comprising daily doses of aromatase inhibitor for administration during assisted reproduction or ovarian stimulation cycles to reduce serum estradiol | CYP19A1, CYP11A1, HSD17B11 | CYP3A4 41/4885LMNA 4437/4885MAPT 4794/4885 |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP3A4 32/4885LMNA 1582/4885MAPT 4649/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | CYP3A4 532/4885LMNA 1025/4885MAPT 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.